Raúl Rabadán declines CNIO directorship citing politicization and instability at Spanish cancer research center
By
Nuño Domínguez
Front-window bakery material. Catches the eye, delivers the goods.
Summary
Raúl Rabadán, the bioinformatician selected as the new scientific director of Spain's National Center for Oncological Research (CNIO), has declined the position. In a letter to staff, he cited the institution's "politicization," "instability," and "continuous controversies" as reasons for his decision. His appointment had been announced as a major acquisition by Spain's Ministry of Science in September 2025, but Rabadán ultimately chose not to take the role, which was set to begin in May. The decision comes amid ongoing corruption and scandal issues plaguing the public research organization.
Key quotes
· 1 pulledEl fallido director científico del Centro Nacional de Investigaciones Oncológicas (CNIO), Raúl Rabadán, ha explicado este miércoles a la plantilla que ha decidido no asumir su cargo al frente de la institución porque la considera 'inestable', 'politizada' y marcada por 'controversias continuas'.
You might also wanna read
NIH Halts Tuberculosis Research Over Unfounded 'Dangerous' Gain-of-Function Concerns
A UC Berkeley professor and NIH grant recipient describes how the NIH abruptly ordered them to stop their tuberculosis research, deeming it
statnews.com·7mo ago
EU Science Diplomat Criticizes US for Undermining Global Scientific Leadership
The European Commission's top science diplomat, Signe Ratso, has criticized the United States for damaging its global scientific leadership
sciencebusiness.net·5mo agoxAI loses bid to halt California AI data disclosure law
U.S. science agency moves to restrict foreign scientists from its labs
Ben Folds Warns National Symphony Orchestra 'May Not Survive' After Trump's Kennedy Center Takeover
Ben Folds, former artistic advisor to the National Symphony Orchestra, published an open letter warning that the NSO "may not survive" follo
Pitchfork·2h ago
HHS Ends mRNA Vaccine Development Under BARDA Following Review
The U.S. Department of Health and Human Services (HHS) has announced the wind-down of its mRNA vaccine development activities under BARDA, i
hhs.gov·10mo ago